Report Description

Saudi Arabia pharmaceutical market is expected to grow at a significant CAGR in the forecast period. The rise in the prevalence of lifestyle diseases owing to the adoption of a sedentary lifestyle thereby leaving less time for physical activities. The surge in consumption of junk food and high sugar-containing food items and beverages is affecting the health of consumers adversely. The development of healthcare infrastructure and the increase in efforts by the leading authorities for technological up-gradation of the existing system is fostering the growth of the pharmaceutical market. An increase in awareness among the consumers regarding the health insurance plans and reimbursement policies is aiding in increasing the demand for quality healthcare treatment services which in turn is fueling the pharmaceutical market growth in the next five years.

Additionally, an increase in the occurrence of non-communicable diseases requiring drug prescription for treatment is fueling the demand for the pharmaceutical market. The rise in disposable income among middle-class families is increasing the expenditure capacity of consumers to afford branded pharmaceutical drugs. The rise in initiatives taken by the government to promote foreign direct investment for the development of the pharmaceutical sector and privatization of the hospitals is influencing the pharmaceutical market growth.


Moreover, the changes in lifestyle preferences and prevalence of circulatory disorders are the major driver for the growth of this segment. Also, the increase in the occurrence of sugar level disorder is fueling the occurrence of diabetes among the individuals which is a major reason responsible for the growth of cardiovascular disorders in the region.


Rising prevalence of chronic diseases

In Saudi Arabia, hypertension, diabetes, obesity, heart diseases, and asthma are reported as the common chronic diseases. The rising prevalence of diabetes and cancer in both male and female Arab populations is predicted to boost the Saudi Arabia pharmaceutical pharmaceuticals market throughout the forecast period. According to the World Health Organization (WHO), Saudi Arabia has the second highest diabetes prevalence rate in the Middle East region and the seventh highest diabetes prevalence rate in the world. Moreover, according to Global Cancer Observatory, in 2020, around 27,885 new cancer cases were reported in Saudi Arabia. Breast Cancer, Thyroid Cancer, Colorectum Cancer, Prostate Cancer and Leukemia Cancer were the most prevalent types of cancer cases reported in 2020. It is believed that around 7 million individuals are diabetic, with an additional 3 million having pre-diabetes. According to some research studies, in Saudi Arabia, NCDs are responsible for 73% of all deaths. Cardiovascular diseases are the leading cause of chronic deaths, accounting for 37% of total deaths, followed by cancer at 10%, then diabetes at 3%, respiratory diseases at 3% and other NCDs at 20%. According to a report by the International Diabetes Federation, the prevalence of diabetes in Saudi Arabia is one of the highest in the world, with around 17.7% of the population affected by the disease. This rise in chronic diseases has led to an increased demand for medicines and healthcare services, driving growth in the pharmaceutical market.


Rapid improvement in healthcare sector

The Saudi Arabia Government and several multinational companies are working together to improve the healthcare sector. For instance, in 2019, the Saudi Arabian General Investment Authority (SAGIA) and a British pharmaceutical company GlaxoSmithKline signed a local agreement to improve its production capacity as soon as possible, and relatively produce a variety of Saudi-related employment. Additionally, the Saudi Ministry of Health (MoH) provides an integrated network of health-care services covering all regions of the Kingdom. The MoH in Saudi Arabia developed a plan to improve health information system (HIS) within all health-care organizations and facilities. The Saudi Arabian government has implemented several initiatives to encourage growth in the pharmaceutical market. For instance, in 2017, the Saudi Food and Drug Authority (SFDA) launched the Saudi Drug Index, an online database of approved drugs in the country. The database provides information on the approved drugs' prices, indications, dosage, and adverse effects, making it easier for healthcare professionals and patients to access and use the medicines. The government has also been investing in research and development to promote innovation and increase the production of locally made pharmaceuticals products for the overall growth of Saudi Arabia Pharmaceuticals Market.


Recent Developments

The development of new products and new technologies and several mergers or acquisitions of the market players are rising interest to the growth of the market.  For instance, in June 2022, a Gulf Pharmaceutical Industries PJSC Julphar and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, a wholly owned subsidiary of Huadong Medicine Co., Ltd, announced a strategic collaboration in which Julphar will develop, manufacture, and commercialize Liraglutide (including both indications of diabetes and obesity) in 17 Middle East and North Africa (MENA) countries such as the UAE, Saudi Arabia, Egypt, Kuwait, Oman, Bahrain, and others.

Additionally, in December 2021, a leading Saudi pharmaceutical company namely Tabuk Pharmaceutical Manufacturing Company, and a leading Chinese innovation-driven pharmaceutical company namely Jiangsu Hansoh Pharmaceutical Group Co., Ltd., have announced an agreement to commercialize several oncology and specialty products in Saudi Arabia and other Middle Eastern markets. Tabuk Pharmaceuticals will have exclusive rights to hold the marketing authorization for these pharmaceuticals, responsible for registering, importing, and promoting medications in Saudi Arabia and Middle Eastern nations under the conditions of this agreement. In March 2020, the Ministry of Health of Saudi Arabia signed a memorandum of

understanding with Sanofi to start localizing and transferring insulin technology in the kingdom.

Additionally, in September 2019, a South Korean pharmaceutical company namely Celltrion Inc., launched its breast and gastric cancer biosimilar drug ‘Herzuma’ in Iraq. The drug was also launched in Jordan, Israel, the United Arab Emirates, Saudi Arabia, and Morocco. Hence, the key players are involved in launching new drugs, which is expected to propel the growth of the market over the forecast period.


Dependency on imports to hinder market growth

Saudi Arabia market growth is expected to hinder in the forecasted period due to increased drug recalls and withdrawals by the Saudi Ministry of Health (MOH). For instance, in August 2019, a Saudi Arabian based company namely Julphar recalled a single batch of Laxocodyl suppository (10mg) due to owing a labeling error on the blister pack. Laxocodyl is used to relieve constipation in adults, but the label of batch 0093's blister pack falsely indicated that the medicine is for children. Therefore, with collaboration of the UAE Ministry of Health and Prevention, the business issued an urgent recall notice and worked with its distributors to guarantee that all boxes in the designated batch were returned. The population of Saudi Arabia relies heavily on pharmaceutical imports. Saudi Arabia imports around 80% of its medications from other nations. For instance, according to the International Trade Administration's (ITA) latest data on exports in October 2019, Saudi Arabia accounted for 59.4% of Gulf pharmaceutical purchases. Therefore, the above-mentioned factors are likely to hinder the growth of the Saudi Arabia pharmaceutical drugs market.

Download Free Sample Report

Market Segmentation

Saudi Arabia Pharmaceutical Market is segmented based on drug type, product type, application, distribution channel, region, and company. Based on drug type, market is further bifurcated into generic drugs, branded drugs. Based on product type, the market is further segmented into prescription drugs, over-the-counter drugs. Based on application, the market is segmented into cardiovascular, musculoskeletal, oncology, anti-infective, metabolic disorder, others. Based on distribution channel, the market is bifurcated into retail pharmacy, hospital pharmacy, e-pharmacy.


Market Players

The major players operating on the pharmaceutical market are Novartis Saudi Arabia, Pfizer Saudi Limited, Glenmark Pharmaceuticals Saudi Arabia, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Tabuk Pharmaceuticals Manufacturing Co., Jamjoom Pharmaceuticals Co, Julphar Pharmaceuticals, GlaxoSmithKline Saudi Arabia Limited, Baxter Company Limited (BCL) Saudi Arabia, AstraZeneca Saudi Arabia, and others. Major companies are developing advanced technologies and launching new services to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new service developments. 



Base Year


Historical Data

2018 – 2022

Estimated Year


Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million and CAGR for 2018-2022 and 2023E-2028F

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         Drug Type

·         Product Type

·         Application

·         End User 

·         Region

·         Company

Regional scope

Western Region, Northern & Central Region, Eastern Region, Southern Region

Key companies profiled

Novartis Saudi Arabia, Pfizer Saudi Limited, Glenmark Pharmaceuticals Saudi Arabia, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Tabuk Pharmaceuticals Manufacturing Co., Jamjoom Pharmaceuticals Co, Julphar Pharmaceuticals, GlaxoSmithKline Saudi Arabia Limited, Baxter Company Limited (BCL) Saudi Arabia, AstraZeneca Saudi Arabia.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Report Scope:

In this report, Saudi Arabia pharmaceutical market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Saudi Arabia Pharmaceutical Market, By Drug Type:
    • Generic Drugs
    • Branded Drugs
  • Saudi Arabia Pharmaceutical Market, By Product Type:
    • Prescription Drugs
    • Over-The-Counter Drugs
  • Saudi Arabia Pharmaceutical Market, By Application:
    • Cardiovascular
    • Musculoskeletal
    • Oncology
    • Anti-infective
    • Metabolic Disorder
    • Others
  • Saudi Arabia Pharmaceutical Market, By End User:
    • Retail Pharmacy
    • Hospital Pharmacy
    • E-Pharmacy
  • Saudi Arabia Pharmaceutical Market, By Region:
    • Western Region
    • Northern & Central Region
    • Eastern Region
    • Southern Region

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Saudi Arabia pharmaceutical market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Saudi Arabia pharmaceutical market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected] 

Table of content

1.     Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Saudi Arabia Pharmaceutical Market

4.    Executive Summary

5.    Voice of Customers

6.    Saudi Arabia Pharmaceutical Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Drug Type (Generic Drugs, Branded Drugs)

6.2.2.     By Product Type (Prescription Drugs, Over-The-Counter Drugs)

6.2.3.     By Application (Cardiovascular, Musculoskeletal, Oncology, Anti-infective, Metabolic Disorder, Others)

6.2.4.     By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-Pharmacy)

6.2.5.     By Region

6.2.6.     By Company (2022)

6.3.  Product Market Map

7.    Saudi Arabia Generic Drugs Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Product Type

7.2.2.     By Application

7.2.3.     By Distribution Channel

8.    Saudi Arabia Branded Drugs Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Product Type

8.2.2.     By Application

8.2.3.     By Distribution Channel

9.    Market Dynamics

9.1.     Drivers

9.2.     Challenges

10.  Market Trends & Developments

11.  Policy & Regulatory Landscape

12.  Saudi Arabia Economic Profile

13.  Competitive Landscape

13.1.    Competition Outlook

13.2.    Company Profiles

13.2.1.  Novartis Saudi Arabia

13.2.2.  Pfizer Saudi Limited

13.2.3.  Glenmark Pharmaceuticals Saudi Arabia

13.2.4.  Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)

13.2.5.  Tabuk Pharmaceuticals Manufacturing Co.

13.2.6.  Jamjoom Pharmaceuticals Co

13.2.7.  Julphar Pharmaceuticals

13.2.8.  GlaxoSmithKline Saudi Arabia Limited

13.2.9.  Baxter Company Limited (BCL) Saudi Arabia

13.2.10.                AstraZeneca Saudi Arabia

14.  Strategic Recommendations

15. About Us & Disclaimer

Figures and Tables

Frequently asked questions


Saudi Arabia Pharmaceutical Market is expected to grow at impressive rate on account of increasing numbers of chronic disorders, and rise in geriatric population, etc.


The generic segment will dominate the Saudi Arabia Pharmaceutical Market due to rising ischemic and heart strokes in the country.


Novartis Saudi Arabia, Pfizer Saudi Limited, Glenmark Pharmaceuticals Saudi Arabia, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Tabuk Pharmaceuticals Manufacturing Co., Jamjoom Pharmaceuticals Co, Julphar Pharmaceuticals, GlaxoSmithKline Saudi Arabia Limited, Baxter Company Limited (BCL) Saudi Arabia, AstraZeneca Saudi Arabia are some of the leading players operating in the Saudi Arabia Pharmaceutical Market.


The dependency on imports of drugs amongst Saudi Arabia population hinders the growth of the market.


Sakshi Bajaal

Business Consultant
Press Release

Retail Pharmacy Segment to Dominate the Saudi Arabia Pharmaceutical Market

Oct, 2021

Expansion and constant modernization of healthcare sector is expected to drive the demand for Saudi Arabia pharmaceutical market in the forecast period.